The activity of ranbezolid (RBX 7644), a new oxazolidinone, against 306 anaerobes was compared with those of 11 other agents. The MICs at which 50% of the isolates tested are inhibited and those at which 90% of the isolates tested are inhibited (in micrograms per milliliter) were as follows: ranbezolid, 0.03 and 0.5; linezolid, 2 and 4; vancomycin, >16 and >16; teicoplanin, 1 and >16; quinupristin-dalfopristin, 1 and >8; amoxicillinclavulanate, 0.5 and 2; imipenem, 0.125 and 1; clindamycin, 0.25 and 8; metronidazole, 1 and 4; gatifloxacin, 0.5 and 4; and moxifloxacin, 0.5 and 2, respectively. Ranbezolid had very good in vitro activity against both gram-negative and -positive anaerobes.
Anaerobes are frequent causes of human infections, e.g., intra-abdominal infections, especially in immunocompromised and otherwise debilitated hosts. ␤-lactamase production is found in most of the Bacteroides fragilis group and has increasingly been found in Prevotella, Porphyromonas, and Fusobacterium spp. Clindamycin resistance is found in the B. fragilis group and some Clostridium strains, and metronidazole resistance, common among anaerobic gram-positive non-sporeforming rods, has also been found in the B. fragilis group (1) (2) (3) (4) .
Oxazolidinones are a new class of synthetic antimicrobial agents active mainly against gram-positive organisms, including gram-positive anaerobes such as Clostridium spp., Peptostreptococcus spp., and Propionibacterium acnes. Linezolid, the oxazolidinone for which most data are currently available, is active against staphylococci, streptococci, enterococci, and aerobic gram-positive non-spore-forming rods as well as grampositive anaerobes. Activity against gram-negative organisms is less marked. Similar MICs have been described for AZD2563, another experimental oxazolidinone (5, 7, 8, 10, 13) .
Ranbezolid (RBX 7644; Ranbaxy Research Laboratories, New Delhi, India) ( Fig. 1) is a new oxazolidinone with enhanced activity against gram-positive organisms and activity against some fastidious gram-negative organisms. The present study examines the in vitro activity of ranbezolid in comparison with those of linezolid, vancomycin, teicoplanin, quinupristindalfopristin, amoxicillin, amoxicillin-clavulanate, imipenem, clindamycin, metronidazole, gatifloxacin, and moxifloxacin against 306 gram-positive and gram-negative anaerobes.
The strains were all clinical isolates, most of which were isolated during the past 3 years, mostly from the Hershey Medical Center, Hershey, Pa., but also from other hospitals, and were identified by conventional methodology (12) . Each Clostridium difficile isolate was from a separate patient, with some patients from the Hershey Medical Center and others from different hospitals. The possibility of clonality (leading to similar susceptibilities) cannot be excluded in all cases. Prior to testing, organisms were stored in double-strength skim milk (Difco Laboratories, Detroit, Mich.) at Ϫ70°C. Purity throughout the study was checked by Gram stain and colonial morphology. Ranbezolid powder was obtained from Ranbaxy Research Laboratories, and other drugs were obtained from their respective manufacturers. Agar dilution testing for MICs was performed according to NCCLS methodology (11) by using Brucella laked blood agar plates and an inoculum of 10 5 CFU/ spot. Plates were incubated for 48 h in an anaerobic chamber (Coy Laboratory Products, Ann Arbor, Mich.). Standard quality control strains were included in each run.
The MICs are presented in Table 1 . As can be seen, the MICs of ranbezolid for gram-negative and -positive strains were lower than those of linezolid, with the ranbezolid MICs at which 50% (MIC 50 ) and 90% (MIC 90 ) of the isolates tested are inhibited being 0.03 and 0.5 g/ml, respectively, compared with linezolid values of 2.0 and 4.0 g/ml, respectively. The only organisms for which ranbezolid MICs were Ͼ0.5 g/ml were Fusobacterium varium (1.0 g/ml) and the anaerobic grampositive rods, particularly lactobacilli and Propionibacterium acnes (2.0 to 4.0 g/ml). For all other anaerobes, ranbezolid MICs ranged between Յ0.008 and 0.5 g/ml. By contrast, linezolid yielded MICs of Ͻ1.0 g/ml mainly against grampositive anaerobes, with higher MICs against gram-negative anaerobes.
Quinupristin-dalfopristin, vancomycin, and teicoplanin were active predominantly against gram-positive species. Teicopla- nin MICs were several dilutions lower than those of vancomycin for most bacterial groups. Amoxicillin-clavulanate was active against most groups, with an MIC 50 of 0.5 g/ml and an MIC 90 of 2.0 g/ml, while imipenem was also very active, with an MIC 50 of 0.125 g/ml and an MIC 90 of 1.0 g/ml against all strains. Clindamycin was very active, except against some strains in the B. fragilis group, Prevotella species, peptostreptococci, and clostridia, while metronidazole was active against all groups except the anaerobic gram-positive rods (with the exception of some eubacteria). The overall gatifloxacin and 
